Nanomedicine, Volume IIA: Biocompatibility

© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003


References 5500-5599

5500. O. Rokke, A. Revhaug, B. Osterud, K.E. Giercksky, “Increased plasma levels of endotoxin and corresponding changes in circulatory performance in a porcine sepsis model: the effect of antibiotic administration,” Prog. Clin. Biol. Res. 272(1988):247-262.

5501. L. Aussel, R. Chaby, K. Le Blay, J. Kelly, P. Thibault, M.B. Perry, M. Caroff, “Chemical and serological characterization of the bordetella hinzii lipopolysaccharides,” FEBS Lett. 485(17 November 2000):40-46.

5502. J.T.M. Frieling, J.A. Mulder, T. Hendriks, J.H.A.J. Curfs, C.J. van der Linden, R.W. Sauerwein, “Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment,” Antimicrob. Agents Chemother. 41(July 1997):1439-1443.

5503. Robert A. Freitas Jr., “Nanopyrexia,” Foresight Update No. 43, 30 December 2000, pp. 14-16;

5504. R.A. Yokel, “The toxicology of aluminum in the brain: a review,” Neurotoxicology 21(October 2000):813-828.

5505. Paola Scaffidi, Tom Misteli, Marco E. Bianchi, “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,” Nature 418(11 July 2002):191-195.

5506. Simon Brown, Isabelle Heinisch, Ewan Ross, Kate Shaw, Chris D. Buckley, John Savill, “Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment,” Nature 418(11 July 2002):200-203, 139-141 (discussion).

5507. W.G. Brodbeck, J. Patel, G. Voskerician, E. Christenson, M.S. Shive, Y. Nakayama, T. Matsuda, N.P. Ziats, J.M. Anderson, “Biomaterial adherent macrophage apoptosis is increased by hydrophilic and anionic substrates in vivo,” Proc. Natl. Acad. Sci. (USA) 99(6 August 2002):10287-10292.

5508. L. Chibante, D. Heymann, “On the geochemistry of fullerenes: Stability of C60 in ambient air and the role of ozone,” Geochim. Cosmochim. Acta 57(1993):1879-1881.

5509. M.S. de Vries, K. Reihs, H.R. Wendt, W.G. Golden, H. Hunziker, R. Fleming, E. Peterson, S. Chang, “A search for C60 in carbonaceous chondrites,” Geochim. Cosmochim. Acta 57(1993):933-938; Sandra Pizzarello, Yongsong Huang, “Molecular and isotopic analysis of Tagish Lake alkyl dicarboxylic acids,” 64th Annual Meteoritical Society, 2001;

5510. P.R. Buseck, S.J. Tsipursky, R. Hettich, “Fullerenes from the geological environment,” Science 257(1992):215-217.

5511. L. Becker, J.L. Bada, R.E. Winans, J. Hunt, T.E. Bunch, B.M. French, “Fullerenes in the 1.85-billion-year-old Sudbury impact structure,” Science 265(1994):642-644.

5512. D. Heymann, L. Chibante, R. Brooks, W. Wolbach, R. Smalley, “Fullerenes in the Cretaceous-Tertiary boundary layer,” Science 265(1994):645-647.

5513. A. Tsunoda, H.F. Maassab, K.W. Cochran, W.C. Eveland, “Antiviral activity of alpha-methyl-1-adamantanemethylamine hydrochloride,” Antimicrobial Agents Chemother. 5(1965):553-560.

5514. K. Lundahl, J. Schut, J.L. Schlatmann, G.B. Paerels, A. Peters, “Synthesis and antiviral activities of adamantane spiro compounds. 1. Adamantane and analogous spiro-3’-pyrrolidines,” J. Med. Chem. 15(February 1972):129-132; A. Smit, T. Kralt, A. Peters, R. van Hes, “Synthesis and antiviral activities of adamantane spiro compounds. 2,” J. Med. Chem. 15(February 1972):132-136.

5515. A. Mathur, A.S. Beare, S.E. Reed, “In vitro antiviral activity and preliminary clinical trials of a new adamantane compound,” Antimicrob. Agents Chemother. 4(October 1973):421-426.

5516. K. Aigami, Y. Inamoto, N. Takaishi, K. Hattori, A. Takatsuki, “Biologically active polycycloalkanes. 1. Antiviral adamantane derivatives,” J. Med. Chem. 18(July 1975):713-721.

5517. R. Pellicciari, M.C. Fioretti, P. Cogolli, M. Tiecco, “Adamantane derivatives of biological interest. Synthesis and antiviral activity of 2-(1-adamantyl)imidazole derivatives,” Arzneimittelforschung 30(December 1980):2103-5.

5518. W.C. Koff, J.L. Elm Jr., S.B. Halstead, “Suppression of dengue virus replication in vitro by rimantadine hydrochloride,” Am. J. Trop. Med. Hyg. 30(January 1981):184-189.

5519. A. Papadaki-Valiraki, S. Papakonstantinou-Garoufalias, P. Marakos, A. Chytyroglou-Lada, M. Hosoya, J. Balzarini, E. de Clercq, “Synthesis, antifungal, antibacterial and antiviral effects of some adamantaneketoxime ethers,” Farmaco 48(August 1993):1091-1102.

5520. G. Fytas, P. Marakos, N. Kolocouris, G.B. Foscolos, N. Pouli, A. Vamvakides, S. Ikeda, E. De Clercq, “3-Cyclopentyl-1-adamantanamines and adamantanemethanamines. Antiviral activity evaluation and convulsions studies,” Farmaco 49(October 1994):641-647.

5521. R. Kandel, K.L. Hartshorn, “Prophylaxis and treatment of influenza virus infection,” BioDrugs 15(2001):303-323.

5522. K. Van Derpoorten, J. Balzarini, E. De Clercq, J.H. Poupaert, “Anti-HIV activity of N-1-adamantyl-4-aminophthalimide,” Biomed. Pharmacother. 51(October 1997):464-468.

5523. J. Vamecq, K. Van Derpoorten, J.H. Poupaert, J. Balzarini, E. De Clercq, J.P. Stables, “Anticonvulsant phenytoinergic pharmacophores and anti-HIV activity--preliminary evidence for the dual requirement of the 4-aminophthalimide platform and the N-(1-adamantyl) substitution for antiviral properties,” Life Sci. 63(1998):PL267-PL274.

5524. M.E. Burstein, A.V. Serbin, T.V. Khakhulina, I.V. Alymova, L.L. Stotskaya, O.P. Bogdan, E.E. Manukchina, V.V. Jdanov, N.K. Sharova, A.G. Bukrinskaya, “Inhibition of HIV-1 replication by newly developed adamantane-containing polyanionic agents,” Antiviral Res. 41(April 1999):135-144.

5525. J.K. Chakrabarti, M.J. Foulis, T.M. Hotten, S.S. Szinai, A. Todd, “Adamantanealkanamines as potential antidepressant and anti-Parkinson agents,” J. Med. Chem. 17(June 1974):602-609.

5526. J. Kornhuber, K. Schoppmeyer, P. Riederer, “Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex,” Neurosci. Lett. 163(12 December 1993):129-131.

5527. J. Kornhuber, G. Quack, W. Danysz, K. Jellinger, W. Danielczyk, W. Gsell, P. Riederer, “Therapeutic brain concentration of the NMDA receptor antagonist amantadine,” Neuropharmacology 34(July 1995):713-721.

5528. M. Merello, M.I. Nouzeilles, A. Cammarota, R. Leiguarda, “Effect of memantine (NMDA antagonist) on Parkinson’s disease: a double-blind crossover randomized study,” Clin. Neuropharmacol. 22(September-October 1999):273-276.

5529. S.F. Zakrzewski, C. Dave, F. Rosen, “Comparison of the antitumor activity and toxicity of 2,4-diamino-5-(1-adamantyl)-6-methylpyrimidine and 2,4-diamino-5-(1-adamantyl)-6-ethylpyrimidine,” J. Natl. Cancer Inst. 60(May 1978):1029-1033.

5530. M.A. el-Sherbeny, “Synthesis, antitumor activity, and anti-HIV-1 testing of certain heterocyclic systems containing an adamantane nucleus,” Arch. Pharm. (Weinheim) 333(October 2000):323-328; H.T. Nagasawa, J.A. Elberling, F.N. Shirota, “Latentiated forms of the transport-inhibitory alpha-amino acid adamantanine,” J. Pharm. Sci. 69(September 1980):1022-1025.

5531. S. Siena, S. Villa, M. Bregni, G. Bonnadonna, A.M. Gianni, “Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin,” Blood 69(January 1987):345-348.

5532. P. Liu, P.J. Cheng, T.S. Ing, J.T. Daugirdas, R. Jeevanandhan, L.S. Soung, S. Galinis, “In vitro binding of amantadine to plasma proteins,” Clin. Neuropharmacol. 7(1984):149-151; T.S. Ing, P.J. Cheng, M.J. Wu, J.T. Daugirdas, L.S. Soung, “Plasma protein-binding of amantadine in maintenance hemodialysis patients,” Int. J. Artif. Organs 7(July 1984):235.

5533. Y. Yang, P.M. Cardarelli, K. Lehnert, S. Rowland, G.W. Krissansen, “LPAM-1 (integrin alpha 4 beta 7)-ligand binding: overlapping binding sites recognizing VCAM-1, MAdCAM-1 and CS-1 are blocked by fibrinogen, a fibronectin-like polymer and RGD-like cyclic peptides,” Eur. J. Immunol. 28(March 1998):995-1004; P.M. Cardarelli, R.R. Cobb, D.M. Nowlin, W. Scholz, F. Gorcsan, M. Moscinski, M. Yasuhara, S.L. Chiang, T.J. Lobl, “Cyclic RGD peptide inhibits alpha 4 beta 1 interaction with connecting segment 1 and vascular cell adhesion molecule,” J. Biol. Chem. 269(15 July 1994):18668-18673.

5534. H.T. Nagasawa, J.A. Elberling, F.N. Shirota, “Potential latentiation forms of biologically active compounds based on action of leucine aminopeptidase. Dipeptide derivatives of the tricycloaliphatic alpha-amino acid, adamantanine,” J. Med. Chem. 18(August 1975):826-830.

5535. R.E. White, M.B. McCarthy, K.D. Egeberg, S.G. Sligar, “Regioselectivity in the cytochromes P-450: control by protein constraints and by chemical reactivities,” Arch. Biochem. Biophys. 228(1 February 1984):493-502.

5536. C.H. Hassall, W.H. Johnson, A.J. Kennedy, N.A. Roberts, “A new class of inhibitors of human leucocyte elastase,” FEBS Lett. 183(22 April 1985):201-205; A.J. Kennedy, A. Cline, U.M. Ney, W.H. Johnson, N.A. Roberts, “The effect of a peptide aldehyde reversible inhibitor of elastase on a human leucocyte elastase-induced model of emphysema in the hamster,” Eur. J. Respir. Dis. 71(November 1987):472-478.

5537. D.H. Barton, E. Csuhai, D. Doller, N. Ozbalik, G. Balavoine, “Mechanism of the selective functionalization of saturated hydrocarbons by Gif systems: relationship with methane monooxygenase,” Proc. Natl. Acad. Sci. (USA) 87(May 1990):3401-3404;

5538. N. Tsuzuki, T. Hama, M. Kawada, A. Hasui, R. Konishi, S. Shiwa, Y. Ochi, S. Futaki, K. Kitagawa, “Adamantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety,” J. Pharm. Sci. 83(April 1994):481-484.

5539. B.M. Kurinenko, N.V. Kalacheva, P.Iu. Muratov, “Preparation and antiviral properties of Bacillus intermedius ribonuclease modified by chloranhydride of adamantanecarboxylic acid,” Antibiot. Khimioter. 40(September 1995):17-19. In Russian.

5540. R.I. Christopherson, “Partial inactivation of chorismate mutase-prephenate dehydrogenase from Escherichia coli in the presence of analogues of chorismate,” Int. J. Biochem. Cell Biol. 29(April 1997):589-594.

5541. H.S. Overkleeft, G.H. Renkema, J. Neele, P. Vianello, I.O. Hung, A. Strijland, A.M. van der Burg, G.J. Koomen, U.K. Pandit, J.M. Aerts, “Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase,” J. Biol. Chem. 273(9 October 1998):26522-26527;

5542. B.M. Kessler, D. Tortorella, M. Altun, A.F. Kisselev, E. Fiebiger, B.G. Hekking, H.L. Ploegh, H.S. Overkleeft, “Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits,” Chem. Biol. 8(September 2001):913-929.

5543. R. Maltais, V. Luu-The, D. Poirier, “Synthesis and optimization of a new family of type 3 17 beta-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry,” J. Med. Chem. 45(31 January 2002):640-653.

5544. R.A. Magarian, W.G. Sorenson, “Adamantanamine derivatives. Antimicrobial activities of certain Mannich bases,” J. Med. Chem. 19(January 1976):186-189; M. Takahashi, M. Pischetsrieder, V.M. Monnier, “Isolation, purification, and characterization of amadoriase isoenzymes (fructosyl amine-oxygen oxidoreductase EC 1.5.3) from Aspergillus sp.,” J. Biol. Chem. 272(7 February 1997):3437-3443,; A. Orzeszko, B. Kaminska, G. Orzeszko, B.J. Starosciak, “Synthesis and antimicrobial activity of new adamantane derivatives II.,” Farmaco 55(September-October 2000):619-623; A. Orzeszko, R. Gralewska, B.J. Starosciak, Z. Kazimierczuk, “Synthesis and antimicrobial activity of new adamantane derivatives I.,” Acta Biochim. Pol. 47(2000):87-94.

5545. M. Garcia Gil, M. Sanchez Crespo, “Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes,” Immunopharmacology 6(December 1983):317-325.

5546. E. Albrecht-Goepfert, H. Schempp, E.F. Elstner, “Modulation of the production of reactive oxygen species by pre-activated neutrophils by aminoadamantane derivatives,” Biochem. Pharmacol. 56(1 July 1998):141-152.

5547. H. Schempp, E. Albrecht-Goepfert, E.F. Elstner, “Detection of the production of reactive oxygen species by neutrophils in whole blood: modulation by adamantanes and triggering by Fe(3+)-ions,” Z. Naturforsch. [C] 54(July-August 1999):562-568.

5548. W.C. Koff, D.L. Peavy, V. Knight, “Inhibition of in vitro proliferative responses of human lymphocytes by rimantadine hydrochloride,” Infect. Immun. 23(March 1979):665-669.

5549. C. Clark, M.M. Woodson, H.T. Nagasawa, “Inhibition of lymphocyte proliferation by amantadine and its isomer, 2-aminoadamantane; impact on Lyt-2+ T cells while sparing L3T4+ T cells,” Immunopharmacology 21(January-February 1991):41-50.

5550. J.D. Brain, R.M. Molina, M.M. DeCamp, A.E. Warner, “Effects of a perfluorochemical emulsion on the fate of circulating Pseudomonas aeruginosa,” Am. J. Physiol. 276(June 1999):L1037-L1045;

5551. G.I. Nezhinskaia, E.A. Val’dman, P.G. Nazarov, T.A. Voronina, “Immunotropic activity of a potential antiparkinson agent himantane,” Eksp. Klin. Farmakol. 64(March-April 2001):60-63. In Russian.

5552. S. Gobec, U. Urleb, S. Simcic, B. Wraber, “Synthesis and modulation of cytokine production by two new adamantane substituted acyclic desmuramyldipeptide analogs,” Pharmazie 56(July 2001):523-526.

5553. W.C. Koff, J.L. Elm Jr., S.B. Halstead, “Inhibition of dengue virus replication by amantadine hydrochloride,” Antimicrob. Agents Chemother. 18(July 1980):125-129.

5554. A. Sioufi, F. Pommier, “Gas chromatographic determination of amantadine hydrochloride (Symmetrel) in human plasma and urine,” J. Chromatogr. 183(11 July 1980):33-39.

5555. V.W. Horadam, J.G. Sharp, J.D. Smilack, B.H. McAnalley, J.C. Garriott, M.K. Stephens, R.C. Prati, D.C. Brater, “Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function,” Ann. Intern. Med. 94(April 1981):454-458.

5556. C. Koppel, J. Tenczer, “A revision of the metabolic disposition of amantadine,” Biomed. Mass Spectrom. 12(September 1985):499-501.

5557. C. Koppel, J. Tenczer, E. Rutten, F. Klaschka, “The metabolism of tromantadine,” Biomed. Mass Spectrom. 12(September 1985):487-488.

5558. S.M. Antonov, J.W. Johnson, N.Y. Lukomskaya, N.N. Potapyeva, V.E. Gmiro, L.G. Magazanik, “Novel adamantane derivatives act as blockers of open ligand-gated channels and as anticonvulsants,” Mol. Pharmacol. 47(March 1995):558-567; L.G. Magazanik, S.L. Buldakova, M.V. Samoilova, V.E. Gmiro, I.R. Mellor, P.N. Usherwood, “Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives,’ J. Physiol. 505(15 December 1997):655-663.

5559. J.W. Dear, K. Wirth, G.K. Scadding, J.C. Foreman, “Characterization of the bradykinin receptor in the human nasal airway using the binding of [125I]-Hoe 140,” Br. J. Pharmacol. 119(November 1996):1054-1062; H. Matsuda, K. Hayashi, K. Arakawa, M. Naitoh, E. Kubota, M. Honda, A. Matsumoto, H. Suzuki, T. Yamamoto, F. Kajiya, T. Saruta, “Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin,” J. Am. Soc. Nephrol. 10(November 1999):2272-2282; G. Reyes-Cruz, J. Vazquez-Prado, W. Muller-Esterl, L. Vaca, “Regulation of the human bradykinin B2 receptor expressed in sf21 insect cells: a possible role for tyrosine kinases,” J. Cell Biochem. 76(January 2000):658-673.

5560. M. Fujio, T. Kuroita, Y. Sakai, H. Nakagawa, Y. Matsumoto, “N-[1-(2-Phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists,” Bioorg. Med. Chem. Lett. 10(6 November 2000):2457-2461.

5561. R. Vegners, I. Shestakova, I. Kalvinsh, R.M. Ezzell, P.A. Janmey, “Use of a gel-forming dipeptide derivative as a carrier for antigen presentation,” J. Pept. Sci. 1(November-December 1995):371-378.

5562. W.C. Koff, D.L. Peavy, V. Knight, “Inhibition of in vitro proliferative responses of human lymphocytes by rimantadine hydrochloride,” Infect. Immun. 23(March 1979):665-669.

5563. E. Antoniadou-Vyza, N. Avramidis, A. Kourounakis, L. Hadjipetrou, “Anti-inflammatory properties of new adamantane derivatives. Design, synthesis, and biological evaluation,” Arch. Pharm. (Weinheim) 331(February 1998):72-78.

5564. R.E. Small, “Diclofenac sodium,” Clin. Pharm. 8(August 1989):545-558.

5565. N. Yoshida, T. Kiyohara, M. Fukui, T. Atsumi, S. Ogino, M. Inaba, S. Tsukagoshi, Y. Sakurai, “Antitumor activities of newly synthesized 5-carbamoyl-1 H-imidazol-4yl 1-adamantanecarboxylate and 5-carbamoyl-1H-imidazol-4yl piperonylate,” Cancer Res. 40(October 1980):3810-3814; A. Chimirri, R. Gitto, S. Grasso, A.M. Monforte, M. Zappala, “Synthesis and antitumor activity evaluation of 1-[(arylidene)amino]adamantanes,” Farmaco 49(October 1994):649-651; J.J. Wang, S.S. Wang, C.F. Lee, M.A. Chung, Y.T. Chern, “In vitro antitumor and antimicrobial activities of N-substituents of maleimide by adamantane and diamantane,” Chemotherapy 43(May-June 1997):182-189.

5566. I. Habus, Q. Zhao, S. Agrawal, “Synthesis, hybridization properties, nuclease stability, and cellular uptake of the oligonucleotide--amino-beta-cyclodextrins and adamantane conjugates,” Bioconjug. Chem. 6(July-August 1995):327-331.

5567. M.E. Herr, R.A. Johnson, H.C. Murray, L.M. Reineke, G.S. Fonken, “The microbiological oxygenation of acylated 1-adamantanamines. Stereochemistry and structural determinations,” J. Org. Chem. 33(August 1968):3201-3207; S.A. Selifonov, “Microbial oxidation of adamantanone by Pseudomonas putida carrying the camphor catabolic plasmid,” Biochem. Biophys. Res. Commun. 186(14 August 1992):1429-1436; I.I. Starovoitov, E.I. Bagrii, A.V. Slepen’kin, V.M. Adanin, K.I. Kashparov, A.M. Boronin, N.A. Plate, R.V. Petrov, “Microbiological transformation of adamantanes,” Dokl. Akad. Nauk. 334(January 1994):241-244 (in Russian).

5568. V. Kunzelmann, “Oral combination therapy of zoster neuralgia. Pain reduction by 1-adamantanamine sulfate and carbamazepine per os,” Fortschr. Med. 111(30 September 1993):423-425. In German.

5569. W.G. van Ketel, “Systemic contact-type dermatitis by derivatives of adamantane?” Derm. Beruf. Umwelt 36(January-February 1988):23-24.

5570. M.G. Garrino, J.C. Henquin, “Adamantane derivatives: a new class of insulin secretagogues,” Br. J. Pharmacol. 90(March 1987):583-591.

5571. S.Y. Choo, K. Vollherbst, A. Keith, W. Snipes, “Effects of adamantane derivatives on the stability and assembly of bacteriophage PM2,” Can. J. Microbiol. 28(July 1982):897-900.

5572. U. Haacke, W. Wesemann, “Induction of the platelet release reaction by 1.3-dimethyl-5-aminoadamantane, a new adamantane derivative,” Thromb. Haemost. 37(28 February 1977):62-72.

5573. M.K. Jain, N.Y. Wu, T.K. Morgan Jr., M.S. Briggs, R.K. Murray Jr., “Phase transition in a lipid bilayer. II. Influence of adamantane derivatives,” Chem. Phys. Lipids 17(September 1976):71-78.

5574. H.J. Ringold, T. Bellas, A. Clark, “Adamantanone as a probe for the dimensions and characteristics of the substrate binding pocket of certain alcohol dehydrogenases,” Biochem. Biophys. Res. Commun. 27(5 May 1967):361-367; V.A. Kalninya, M.K. Indulen, “Effect of adamantane derivatives on the activity of orthomyxovirus RNA-dependent RNA polymerase,” Acta Virol. 20(August 1976):343-346.

5575. J.S. Wishnok, “Medicinal properties of adamantane derivatives,” J. Chem. Educ. 50(November 1973):780-789.

5576. A. Mirmohammadsadegh, J. Maschke, E. Basner-Tschakarjan, A. Bar, U.R. Hengge, “Induction of acute phase response genes in keratinocytes following exposure to oligodeoxynucleotides,” J. Mol. Med. 80(June 2002):377-383.

5577. E. Ravot, G. Comolli, F. Lori, J. Lisziewicz, “High efficiency lentiviral gene delivery in non-dividing cells by deoxynucleoside treatment,” J. Gene Med. 4(March-April 2002):161-169.

5578. M. Hiraki, “Intracellular DNA and RNA in the course of tumor cell growth,” Kurume Med. J. 41(1994):1-13.

5579. S.R. Scholz, C. Korn, O. Gimadutdinow, M. Knoblauch, A. Pingoud, G. Meiss, “The effect of ICAD-S on the formation and intracellular distribution of a nucleolytically active caspase-activated DNase,” Nucleic Acids Res. 30(15 July 2002):3045-3051; T. Simmons, M. Lipman, L.D. Hodge, “Uptake and early fate of metaphase chromosomes ingested by the Wi-L2 human lymphoid cell line,” Somatic Cell Genet. 4(January 1978):55-76.

5580. A.L. Bothwell, S. Altman, “Partial purification and properties of an endoribonuclease isolated from human KB cells,” J. Biol. Chem. 250(25 February 1975):1451-1459.

5581. T. Horikoshi, J. Page, G. Lei, H. Brysk, I. Arany, S.K. Tyring, M.M. Brysk, “Proteasomal RNase activity in human epidermis,” In Vivo 12(March-April 1998):155-158.

5582. L. Qiu, A. Moreira, G. Kaplan, R. Levitz, J.Y. Wang, C. Xu, K. Drlica, “Degradation of hammerhead ribozymes by human ribonucleases,” Mol. Gen. Genet. 258(May 1998):352-362.

5583. A.L. ten Asbroek, M. van Groenigen, M. Nooij, F. Baas, “The involvement of human ribonucleases H1 and H2 in the variation of response of cells to antisense phosphorothioate oligonucleotides,” Eur. J. Biochem. 269(January 2002):583-592.

5584. D.W. Cleveland, T.J. Yen, “Multiple determinants of eukaryotic mRNA stability,” New Biol. 1(November 1989):121-126.

5585. G. Guarneros, C. Portier, “Different specificities of ribonuclease II and polynucleotide phosphorylase in 3’mRNA decay,” Biochimie 73(May 1991):543-549.

5586. T. Barlow, M. Berkmen, D. Georgellis, L. Bayr, S. Arvidson, A. von Gabain, “RNase E, the major player in mRNA degradation, is down-regulated in Escherichia coli during a transient growth retardation (diauxic lag),” Biol. Chem. 379(January 1998):33-38.

5587. T. Heise, A. Krones, A. Nath, K. Jungermann, B. Christ, “Parallel acceleration of phosphoenolpyruvate carboxykinase mRNA degradation and increase in ribonuclease activity induced by insulin in cultured rat hepatocytes,” Biol. Chem. 379(July 1998):875-883.

5588. M. Ma, L. Benimetskaya, I. Lebedeva, J. Dignam, G. Takle, C.A. Stein, “Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences,” Nat. Biotechnol. 18(January 2000):58-61.

5589. A. van Hoof, R. Parker, “Messenger RNA degradation: beginning at the end,” Curr. Biol. 12(16 April 2002):R285-R287.

5590. D. Cao, R. Parker, “Computational modeling of eukaryotic mRNA turnover,” RNA 7(September 2001):1192-1212.

5591. P.A. Frischmeyer, A. van Hoof, K. O’Donnell, A.L. Guerrerio, R. Parker, H.C. Dietz, “An mRNA surveillance mechanism that eliminates transcripts lacking termination codons,” Science 295(22 March 2002):2258-2261.

5592. Roy Parker, “Post-transcriptional regulation of gene expression: mechanisms of mRNA degradation,”

5593. Marc A. van Dijk, Jan G.J. van de Winkel, “Human antibodies as next generation therapeutics,” Curr. Opin. Chem. Biol. 5(2001):368-374.

5594. W.B. Shelley, R.P. Arthur, “Mucunain, the active pruritogenic proteinase of cowhage,” Science 122(1955):469-470.

5595. M. Schmelz, R. Schmidt, A. Bickel, H.O. Handwerker, H.E. Torebjork, “Specific C-receptor for itch in human skin,” J. Neurosc. 17(1997):8003-8008.

5596. J.A. Savin, “How should we define itching?” J. Am. Acad. Dermatol. 38(1998):268-269.

5597. R.J. Schwartzman, A. Popescu, “Reflex sympathetic dystrophy,” Curr. Rheumatol. Rep. 4(April 2002):165-169.

5598. “Necrotizing vasculitis,” NLM/Medline Online Medical Encyclopedia;

5599. D.W. Birnbaum, “Safety of maintaining intravenous sites for longer than 48 hours,” J. Clin. Microbiol. 13(May 1981):833-835; C.D. Viall, “Daily access of implanted venous ports: implications for patient education,” J. Intraven. Nurs. 13(September-October 1990):294-296; I. Raad, J. Umphrey, A. Khan, L.J. Truett, G.P. Bodey, “The duration of placement as a predictor of peripheral and pulmonary arterial catheter infections,” J. Hosp. Infect. 23(January 1993):17-26; D.G. Maki, “Infections caused by intravascular devices used for infusion therapy: pathogenesis, prevention, and management,” in A.L. Bisno, F.A. Waldvogel, eds., Infections Associated with Indwelling Medical Devices, Second Edition, American Society for Microbiology Press, Washington, DC, 1994, pp. 155-212; L.A. Mermel, D.G. Maki, “Infectious complications of Swan-Ganz pulmonary artery catheters. Pathogenesis, epidemiology, prevention, and management,” Am. J. Respir. Crit. Care Med. 149(April 1994):1020-1036; Health Canada, “Insertion site care, including dressing and site change intervals,” Infection Control Guidelines: Preventing Infections Associated with Indwelling Intravascular Access Devices, Canada Communicable Disease Report 23S8(December 1997),


Last updated on 16 April 2004